Insights into Microbiome and Metabolic Signatures of Children Undergoing Peanut Oral Immunotherapy.

alpha diversity beta diversity children desensitization food allergy peanut short chain fatty acids tolerance

Journal

Children (Basel, Switzerland)
ISSN: 2227-9067
Titre abrégé: Children (Basel)
Pays: Switzerland
ID NLM: 101648936

Informations de publication

Date de publication:
09 Aug 2022
Historique:
received: 19 06 2022
revised: 15 07 2022
accepted: 25 07 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

Peanut oral immunotherapy has emerged as a novel, active management approach for peanut-allergic sufferers, but limited data exist currently on the role of the microbiome in successful desensitization. We examined the oral and gut microbiome in a cohort of 17 children undergoing peanut oral immunotherapy with the aim to identify the microbiome signatures associated with successful desensitization. We also set out to characterize their fecal metabolic profiles after successful therapy. Participants gradually built up their daily dose from 2 mg (starting dose) to 300 mg (maintenance dose) within approximately 40 weeks. We collected a buccal and stool specimen from each subject at two different time points: at baseline and post-therapy (1 month after reaching maintenance). The oral (buccal) and gut (fecal) microbiome was characterized based on sequencing of 16S rRNA gene amplicons with Illumina MiSeq. Fecal short chain fatty acid levels were measured using liquid chromatography-tandem mass spectrometry. We report increased alpha diversity of the oral microbiome post-therapy and have also identified a significant increase in the relative abundance of oral Actinobacteria, associated with the desensitized state. However, the baseline gut microbiome did not differ from the post-therapy. Additionally, fecal short chain fatty acids increased after therapy, but not significantly. Our research adds to the limited current knowledge on microbiome and metabolic signatures in pediatric patients completing oral immunotherapy. Post-therapy increased trends of fecal fatty acid levels support a role in modulating the allergic response and potentially exerting protective and anti-inflammatory effects alongside successful desensitization. A better understanding of the microbiome-related mechanisms underlying desensitization may allow development of smarter therapeutic approaches in the near future. The oral microbiome composition is altered following successful peanut oral immunotherapy, with a significant increase in alpha diversity and the relative abundance of phylum Actinobacteria. Significant microbiome changes in children completing peanut immunotherapy include increase in alpha-diversity and overrepresentation of Actinobacteria in the oral microbiome, and increased trends for fecal short chain fatty acids, suggesting a protective effect against the allergic response.

Sections du résumé

BACKGROUND BACKGROUND
Peanut oral immunotherapy has emerged as a novel, active management approach for peanut-allergic sufferers, but limited data exist currently on the role of the microbiome in successful desensitization.
OBJECTIVE OBJECTIVE
We examined the oral and gut microbiome in a cohort of 17 children undergoing peanut oral immunotherapy with the aim to identify the microbiome signatures associated with successful desensitization. We also set out to characterize their fecal metabolic profiles after successful therapy.
METHODS METHODS
Participants gradually built up their daily dose from 2 mg (starting dose) to 300 mg (maintenance dose) within approximately 40 weeks. We collected a buccal and stool specimen from each subject at two different time points: at baseline and post-therapy (1 month after reaching maintenance). The oral (buccal) and gut (fecal) microbiome was characterized based on sequencing of 16S rRNA gene amplicons with Illumina MiSeq. Fecal short chain fatty acid levels were measured using liquid chromatography-tandem mass spectrometry.
RESULTS RESULTS
We report increased alpha diversity of the oral microbiome post-therapy and have also identified a significant increase in the relative abundance of oral Actinobacteria, associated with the desensitized state. However, the baseline gut microbiome did not differ from the post-therapy. Additionally, fecal short chain fatty acids increased after therapy, but not significantly.
CONCLUSION CONCLUSIONS
Our research adds to the limited current knowledge on microbiome and metabolic signatures in pediatric patients completing oral immunotherapy. Post-therapy increased trends of fecal fatty acid levels support a role in modulating the allergic response and potentially exerting protective and anti-inflammatory effects alongside successful desensitization. A better understanding of the microbiome-related mechanisms underlying desensitization may allow development of smarter therapeutic approaches in the near future.
CLINICAL IMPLICATION CONCLUSIONS
The oral microbiome composition is altered following successful peanut oral immunotherapy, with a significant increase in alpha diversity and the relative abundance of phylum Actinobacteria.
CAPSULE SUMMARY CONCLUSIONS
Significant microbiome changes in children completing peanut immunotherapy include increase in alpha-diversity and overrepresentation of Actinobacteria in the oral microbiome, and increased trends for fecal short chain fatty acids, suggesting a protective effect against the allergic response.

Identifiants

pubmed: 36010081
pii: children9081192
doi: 10.3390/children9081192
pmc: PMC9406383
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

FEMS Microbiol Ecol. 2012 Jan;79(1):192-202
pubmed: 22029421
J Allergy Clin Immunol. 2012 Feb;129(2):434-40, 440.e1-2
pubmed: 22153774
Pediatr Res. 2018 Mar;83(3):677-686
pubmed: 29155807
Cell Physiol Biochem. 2018;49(1):190-205
pubmed: 30138914
Mediators Inflamm. 2019 Jan 16;2019:9062537
pubmed: 30800003
Lancet. 2014 Apr 12;383(9925):1297-1304
pubmed: 24485709
Cell Mol Gastroenterol Hepatol. 2016 Dec 11;3(2):218-230
pubmed: 28275689
Pediatr Allergy Immunol. 2003 Oct;14(5):378-82
pubmed: 14641608
Allergy. 2018 Jul;73(7):1515-1524
pubmed: 29318631
Ann Allergy Asthma Immunol. 2019 Mar;122(3):276-282
pubmed: 30578857
Pediatr Allergy Immunol. 2018 Aug;29(5):545-554
pubmed: 29624747
Appl Environ Microbiol. 2014 Apr;80(8):2546-54
pubmed: 24532064
Ann Allergy Asthma Immunol. 2020 Aug;125(2):196-201.e1
pubmed: 32278075
Adv Immunol. 2014;121:91-119
pubmed: 24388214
Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13145-50
pubmed: 25157157
J Allergy Clin Immunol. 2012 Apr;129(4):906-20
pubmed: 22365653
J Allergy Clin Immunol. 2017 Apr;139(4):1099-1110
pubmed: 28257972
J Allergy Clin Immunol. 2011 Mar;127(3):654-60
pubmed: 21377034
Allergy. 2009 Aug;64(8):1218-20
pubmed: 19226304
Nat Med. 2019 Mar;25(3):448-453
pubmed: 30643289
Ann Allergy Asthma Immunol. 2014 Nov;113(5):506-12
pubmed: 25442694
J Allergy Clin Immunol. 2014 Sep;134(3):753-5
pubmed: 25086866
Front Immunol. 2017 Nov 10;8:1536
pubmed: 29176981
Pediatr Infect Dis J. 2020 Sep;39(9):e226-e233
pubmed: 32453194
Allergy. 2019 Apr;74(4):799-809
pubmed: 30390309
Mucosal Immunol. 2015 Mar;8(2):265-78
pubmed: 25027601
Clin Exp Allergy. 2017 Apr;47(4):530-539
pubmed: 27976436
Microbiome. 2018 Dec 17;6(1):226
pubmed: 30558668
J Allergy Clin Immunol. 2019 Dec;144(6):1468-1477
pubmed: 31812181
Allergy. 2021 Mar;76(3):927-930
pubmed: 32750160
J Immunol. 2017 Jan 15;198(2):581-589
pubmed: 28069753
J Allergy Clin Immunol. 2011 Mar;127(3):668-76.e1-2
pubmed: 21377036
Clin Exp Allergy. 2014 Jun;44(6):842-50
pubmed: 24330256
J Clin Invest. 2021 Jan 19;131(2):
pubmed: 33463536
J Pharm Biomed Anal. 2017 May 10;138:43-53
pubmed: 28178633
Gut Microbes. 2016 May 3;7(3):189-200
pubmed: 26963409
Allergy. 2018 Oct;73(10):2000-2011
pubmed: 29602225
Cell Host Microbe. 2016 Aug 10;20(2):202-14
pubmed: 27476413
Cell Mol Gastroenterol Hepatol. 2021;11(1):221-248
pubmed: 32795610
J Allergy Clin Immunol Pract. 2016 Mar-Apr;4(2):205-13; quiz 214
pubmed: 26968959
J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):639-41
pubmed: 25213068
Pediatrics. 2011 Jul;128(1):e9-17
pubmed: 21690110
J Allergy Clin Immunol. 2014 Feb;133(2):468-75
pubmed: 24361082
N Engl J Med. 2018 Nov 22;379(21):1991-2001
pubmed: 30449234
J Allergy Clin Immunol. 2009 Aug;124(2):292-300, 300.e1-97
pubmed: 19577283
PLoS One. 2020 Jan 16;15(1):e0227967
pubmed: 31945114
J Immunol. 1997 Aug 15;159(4):1739-45
pubmed: 9257835
ISME J. 2011 Feb;5(2):169-72
pubmed: 20827291
Int J Parasitol Parasites Wildl. 2017 Apr 04;6(3):177-194
pubmed: 28765810
Front Immunol. 2019 Mar 11;10:277
pubmed: 30915065
Sci Rep. 2018 Aug 21;8(1):12500
pubmed: 30131575
J Allergy Clin Immunol Pract. 2021 May;9(5):1879-1889.e14
pubmed: 33359589
J Allergy Clin Immunol. 2017 Jan;139(1):173-181.e8
pubmed: 27522159
Microbiome. 2014 Sep 30;2(1):30
pubmed: 27367037
Ann Allergy Asthma Immunol. 2020 May;124(5):459-465
pubmed: 32001367

Auteurs

Andrea C Blackman (AC)

Department of Pediatrics, Section of Immunology, Allergy and Retrovirology, Texas Children's Hospital, Houston, TX 77030, USA.
Section of Allergy, Immunology & Retrovirology, Baylor College of Medicine, Houston, TX 77030, USA.

Santosh Thapa (S)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, TX 77030, USA.

Alamelu Venkatachalam (A)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, TX 77030, USA.

Thomas D Horvath (TD)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, TX 77030, USA.

Jessica K Runge (JK)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, TX 77030, USA.

Sigmund J Haidacher (SJ)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, TX 77030, USA.

Kathleen M Hoch (KM)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, TX 77030, USA.

Anthony M Haag (AM)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, TX 77030, USA.

Ruth Ann Luna (RA)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, TX 77030, USA.

Aikaterini Anagnostou (A)

Department of Pediatrics, Section of Immunology, Allergy and Retrovirology, Texas Children's Hospital, Houston, TX 77030, USA.
Section of Allergy, Immunology & Retrovirology, Baylor College of Medicine, Houston, TX 77030, USA.

Classifications MeSH